Display options
Share it on

Case Rep Radiol. 2015;2015:731361. doi: 10.1155/2015/731361. Epub 2015 Feb 22.

Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma.

Case reports in radiology

Ramon F Barajas, Miguel H Pampaloni, Jennifer L Clarke, Youngho Seo, Dragana Savic, Randall A Hawkins, Spencer C Behr, Susan M Chang, Mitchel Berger, William P Dillon, Soonmee Cha

Affiliations

  1. Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Avenue, M-391, San Francisco, CA 94143-0628, USA.
  2. Department of Neurological Surgery, University of California, San Francisco, 505 Parnassus Avenue, Room 779 M, San Francisco, CA 94143-0112, USA.
  3. Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Avenue, M-391, San Francisco, CA 94143-0628, USA ; Department of Radiation Oncology, UCSF Long Hospital, 505 Parnassus Avenue, San Francisco, CA 94143-0226, USA.
  4. Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Avenue, M-391, San Francisco, CA 94143-0628, USA ; Department of Neurological Surgery, University of California, San Francisco, 505 Parnassus Avenue, Room 779 M, San Francisco, CA 94143-0112, USA.

PMID: 25793136 PMCID: PMC4352456 DOI: 10.1155/2015/731361

Abstract

We present our initial experience in using single modality fluoromisonidazole (FMISO) PET/MR imaging to noninvasively evaluate the biological effects induced by bevacizumab therapy in a patient treated for recurrent high grade glioma. In this index patient, bevacizumab therapy resulted in the development of nonenhancing tumor characterized by reduced diffusion and markedly decreased FMISO uptake in the setting of maintained CBF and CBV. These observations suggest that the dynamic biological interplay between tissue hypoxia and vascular normalization occurring within treated recurrent high grade glioma can be captured utilizing FMISO PET/MR imaging.

References

  1. AJNR Am J Neuroradiol. 2010 Jan;31(1):60-6 - PubMed
  2. J Magn Reson Imaging. 1999 Jan;9(1):53-60 - PubMed
  3. J Nucl Med. 2004 Nov;45(11):1851-9 - PubMed
  4. J Clin Oncol. 2010 Apr 10;28(11):1963-72 - PubMed
  5. J Neurooncol. 2010 Aug;99(1):49-56 - PubMed
  6. J Nucl Med. 2006 Mar;47(3):410-8 - PubMed
  7. Eur J Nucl Med Mol Imaging. 2006 Dec;33(12 ):1426-31 - PubMed
  8. J Clin Oncol. 2010 Feb 20;28(6):e91-3 - PubMed
  9. J Nucl Med. 1992 Dec;33(12 ):2133-7 - PubMed
  10. J Control Release. 2001 Jul 6;74(1-3):7-25 - PubMed
  11. Nat Rev Cancer. 2008 Jun;8(6):425-37 - PubMed
  12. Clin Cancer Res. 2008 May 1;14 (9):2623-30 - PubMed
  13. Nucl Med Biol. 2002 Feb;29(2):191-7 - PubMed
  14. N Engl J Med. 2005 Mar 10;352(10 ):987-96 - PubMed
  15. AJNR Am J Neuroradiol. 2012 Oct;33(9):1763-70 - PubMed

Publication Types

Grant support